Back to Journals » OncoTargets and Therapy » Volume 12

Sunitinib-and-Chinese herbal medicine-based systematic treatment clinically cured a patient with multiple metastatic primary clear cell carcinoma of the liver: a case report

Authors Sun L, Chen H, Xiao Z, Guo W, Lin L

Received 12 December 2018

Accepted for publication 21 February 2019

Published 12 April 2019 Volume 2019:12 Pages 2823—2828

DOI https://doi.org/10.2147/OTT.S197923

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Cristina Weinberg

Peer reviewer comments 3

Editor who approved publication: Dr William Cho


Lingling Sun,1,2 Hanrui Chen,1,2 Zhiwei Xiao,1,2 Wei Guo,2 Lizhu Lin1,2

1Oncology Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China; 2Integrative Medicine Department, First Clinical School, Guangzhou University of Chinese Medicine, Guangdong, People’s Republic of China

Abstract: Primary clear cell carcinoma of the liver (PCCCL) is a rare and special type of primary hepatocellular carcinoma. However, treatment methods for multiple metastatic PCCCL are lacking. Here, we report the case of a 55-year-old male PCCCL patient with multiple metastatic lesions who was clinically cured by sunitinib-based systematic treatment. This patient was diagnosed with PCCCL in Liver Segment 7, Child–Pugh A liver function, Stage A in November 16, 2009, and received radical excision of the cancer immediately. His disease recurred with multiple metastatic lesions in the liver and other parts of the body, including the retroperitoneal lymph nodes, lung and bilateral adrenal nodules in June 29, 2012. The biopsy results showed that the lung mass was lung metastasis of PCCCL. With Child–Pugh A liver function, Stage C of PCCCL was diagnosed. Sunitinib (37.5 mg, oral, once a day [qd]) in combination with Chinese herbal medicine (CHM) was given. The tumor size steadily reduced, and the lesions were no longer obvious in May 21, 2014. The patient had multiple metastases and is in complete response (CR) state until now. He is considered as clinically cured. From the initial diagnosis of PCCCL, the survival period reached 8 years.

Keywords: hepatocellular carcinoma, primary clear cell carcinoma of the liver, sunitinib, anti-angiogenesis therapy, Chinese herbal medicine


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]